Heartseed Inc. (TYO:219A)
Japan · Delayed Price · Currency is JPY 3,555.00
-125.00 (-3.40%)
Aug 1, 2025, 3:30 PM JST
Heartseed Company Description
Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure.
The company’s lead product candidate is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy.
It also develops products using autologous iPSC and HLA knock-out iPSC. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Heartseed Inc.
| Country | Japan |
| Founded | 2015 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| CEO | Keiichi Fukuda |
Contact Details
Address: 5th Floor, Seavans South Building Tokyo, 105-0023 Japan | |
| Website | heartseed.jp |
Stock Details
| Ticker Symbol | 219A |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | November - October |
| Reporting Currency | JPY |
| ISIN Number | JP3765140003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Keiichi Fukuda | Chief Executive Officer |
| Mutsuki Takano | Chief Financial Officer |
| Kikuo Yasui | Chief Operating Officer |
| Mutsuki Takano | Head of Investor Relations |